Header Logo

Connection

JENNIFER WARGO to Programmed Cell Death 1 Receptor

Back to Details
This is a "connection" page, showing publications JENNIFER WARGO has written about Programmed Cell Death 1 Receptor.
JENNIFER WARGO
Connection Strength
2.232
Programmed Cell Death 1 Receptor
  1. Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer. 2017; 5:10.
    View in: PubMed
    Score: 0.350
  2. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.118
  3. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031.
    View in: PubMed
    Score: 0.118
  4. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 01 12; 12(1):346.
    View in: PubMed
    Score: 0.115
  5. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 02 05; 371(6529):602-609.
    View in: PubMed
    Score: 0.114
  6. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020 02 12; 11(1):853.
    View in: PubMed
    Score: 0.107
  7. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266.
    View in: PubMed
    Score: 0.107
  8. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019 11 05; 116(45):22699-22709.
    View in: PubMed
    Score: 0.105
  9. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
    View in: PubMed
    Score: 0.104
  10. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
    View in: PubMed
    Score: 0.103
  11. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.092
  12. Cancer Evolution during Immunotherapy. Cell. 2017 11 02; 171(4):740-742.
    View in: PubMed
    Score: 0.092
  13. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
    View in: PubMed
    Score: 0.090
  14. Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 06 01; 123(S11):2130-2142.
    View in: PubMed
    Score: 0.089
  15. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017 Jun 27; 117(1):1-7.
    View in: PubMed
    Score: 0.089
  16. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.088
  17. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.083
  18. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 03 01; 10(3):303-313.
    View in: PubMed
    Score: 0.031
  19. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 02; 27(2):301-309.
    View in: PubMed
    Score: 0.029
  20. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565.
    View in: PubMed
    Score: 0.027
  21. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 01; 577(7791):556-560.
    View in: PubMed
    Score: 0.027
  22. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
    View in: PubMed
    Score: 0.025
  23. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018 06; 15(6):382-396.
    View in: PubMed
    Score: 0.024
  24. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.024
  25. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.023
  26. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 2016 Mar-Apr; 22(2):138-46.
    View in: PubMed
    Score: 0.020
  27. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.020
  28. Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res. 2014 Aug; 2(8):714-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.